

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 13312

**Title:** The role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: the jury is still out

**Reviewer code:** 00032020

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-08-17 21:43

**Date reviewed:** 2014-08-18 18:41

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

ESPS Manuscript NO: 13312 Title: The role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: the jury is still out Dr. Lei-bo Xu, et al. Major: This is the latest review about molecular targeted drugs for HCC. I hope that the below points will be revised. In this review, both clinical studies and basic researches were introduced. It had better separate data into two categories more clearly. Also, authors had better add the summarized table. Authors mentioned 'in large-scale randomized phase 3 trials, unfortunately, none of them have shown survival benefits in the first-line, or second-line setting after Sorafenib progression.' However I could not find the data about erlotinib in the referred papers 40, 41 and everolimus in the referred paper 42. Check them again.

## ESPS PEER REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**ESPS manuscript NO:** 13312

**Title:** The role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: the jury is still out

**Reviewer code:** 00680739

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2014-08-17 21:43

**Date reviewed:** 2014-08-21 06:52

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> Existing	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

## COMMENTS TO AUTHORS

1. The authors should have their manuscript proofread by a professional language editor to correct multiple typo, grammar, spelling, and language mistakes. For example, sorafenib need not be capitalized; molecular targeted should be molecularly targeted. By convention, the full name should be given first followed by its abbreviation in parentheses - in a few instances, the authors gave the abbreviation followed by full name in parentheses. 2. The core tip section should be revised to summarize the most important points of the review. As it is written now, it is mostly a repeat of the introduction. 3. The review should be organized into different sections with appropriate headings to help orient the reader. For example, Introduction to liver cancer; Anti-angiogenic drugs used in HCC treatment; Resistance to anti-angiogenic drugs in HCC; Future perspectives etc. 4. Although the title suggests that the review is about anti-angiogenesis therapy in general, much of the review is focused on sorafenib. The authors should try to include as much data as possible about other forms of anti-angiogenic drugs in use or under investigation.